HIGHLIGHTS
- who: Report and colleagues from the (UNIVERSITY) have published the article: Received 06/20/2022 Review began 07/23/2022 Review ended 07/27/2022 Published 07/31/2022, in the Journal: (JOURNAL) of July/31,/2022
- what: In this case, the patient faced a therapeutical challenge for the treatment modalities because of her financial condition.
SUMMARY
Rhabdomyosarcoma (RMS) is a mesenchymal malignancy that is correlated with pediatric malignant soft tissue sarcoma of skeletal muscle that arises from the primitive mesenchymal cell. The prevalence rate of RMS is 0.43 per . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.